News

Biotechnology

BioLineRx Begins Triple Combination Arm of Phase 2a Pancreatic Cancer Trial

BioLineRx Begins Triple Combination Arm of Phase 2a Pancreatic Cancer Trial

Edward Kim | Equities.com |

BL-8040 + Keytruda + chemotherapy combination in metastatic pancreatic cancer (Image: BioLineRx)


CollPlant Announces Positive Clinical Data Published for Tennis Elbow Treatment

Edward Kim | Equities.com |

59% improvement in chronic tennis elbow at 6 months after treatment with recombinant human collagen for soft tissue repair.


DiaMedica Therapeutics Raises $16 Million and Uplists to Nasdaq

Edward Kim | Equities.com |

Lead compound targeting acute ischemic stroke and chronic kidney disease (Image: DiaMedica Therapeutics).


Premier Biomedical Expands Distribution Network for CBD / Hemp Oil Pain Relievers

Edward Kim | Equities.com |

Keep an eye on the 2018 Farm Bill, which may get a vote in Congress next week.


PetVivo: Microcap Play in $18 Billion Veterinary Care Market

Edward Kim | Equities.com |

Lead product for osteoarthritis in dogs and lameness from navicular disease in horses (Image: PetVivo).


Generex Acquires Majority Stake in Olaregen Therapeutix to Enter Wound Healing Market

Edward Kim | Equities.com |

Olaregen's Excellagen (flowable dermal matrix) is FDA approved for wound management in multiple indications (Image: Olaregen Therapeutix)


X4 Pharmaceuticals to Become Public via Reverse Merger with Arsanis

Edward Kim | Equities.com |

Phase 3 trial for X4's lead candidate anticipated to start in the first half of 2019 in WHIM syndrome (Image: X4 Pharmaceuticals).


Applied DNA's SigNature Anti-Theft Molecular Tags Lead to Successful Criminal Convictions

Edward Kim | Equities.com |

Over 131 convictions, with sentences of 625 years to date and more cases in the pipeline (Image: Applied DNA Sciences).


Loxo Oncology Awaiting FDA's Decision Monday on Lead Cancer Therapeutic

Edward Kim | Equities.com |

Monday, Nov. 26th, is the PDUFA date for larotrectinib, Loxo's candidate to treat TRK fusion cancers (Image: Loxo Oncology)


Novimmune and Sobi Get FDA Approval for First Ever Primary HLH Therapy

Edward Kim | Equities.com |

First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)